EGFR and non-small cell lung carcinoma: Thus, the objectives of our study were to evaluate the efficacy and safety of atezolizumab plus bevacizumab in patients with EGFR mutation‐positive, stage IIIB–IV, non‐squamous NSCLC who had been pretreated with EGFR‐TKIs.